<a href="https://laohu8.com/S/SBHMY">Sino Biopharmaceutical</a> Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia
Sino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in a Phase I clinical trial for LM-350, a CDH17 antibody-drug conjugate $(ADC)$, in Australia. LM-350 is an innovative therapy developed by LaNova Medicines Limited, a wholly-owned subsidiary of the company. The clinical study is an open-label, dose escalation and dose expansion Phase I/II trial designed to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of LM-350 in patients with advanced solid tumors. No clinical results have been presented at this time. The company indicated that the trial marks the official entry of LM-350 into the clinical development stage, with plans to advance the project further.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。